Lipid abnormalities in pediatric kidney transplant recipients on steroid withdrawal maintenance immunosuppression.

DRUG therapy for hyperlipidemia; STATINS (Cardiovascular agents); GLOMERULAR filtration rate; STEROIDS; MULTIPLE regression analysis; KIDNEY transplantation; IMMUNOSUPPRESSION; PATIENTS; MANN Whitney U Test; FISHER exact test; HYPERLIPIDEMIA; RISK assessment; PEARSON correlation (Statistics); CHI-squared test; DESCRIPTIVE statistics; BODY mass index; ODDS ratio; COMORBIDITY; DETOXIFICATION (Substance abuse treatment); TRANSPLANTATION of organs, tissues, etc.; CHOLESTEROL; DISEASE risk factors; CHILDREN; ADOLESCENCE

Background: Dyslipidemia is a modifiable risk factor for cardiovascular disease. The prevalence of dyslipidemia in pKTR (pediatric kidney transplant recipients) under modern immunosuppression remains unknown. We determined the prevalence, risk factors, co-morbidities, and treatment patterns of lipid abnormalities in pediatric kidney transplant recipients on steroid withdrawal immunosuppression. Methods: pKTR (age ≤ 21 years) at a single center on steroid withdrawal immunosuppression underwent lipid screening between January 1, 2020, and September 30, 2022. Continuous and categorical variables were compared using the Wilcoxon rank-sum and chi-square or Fisher's exact tests, respectively. The correlation between total cholesterol and BMI (body mass index) was assessed using Pearson's product–moment correlation, and predictors of lipid abnormalities were evaluated using the multivariable logistic regression. Results: A total of 96 patients were included, with a median post-transplant time of 2.5 years (IQR: 1.3–5.4). Of the total, 64.6% (n = 62) of patients had a fasting lipid abnormality. We found a significant linear correlation between total cholesterol and BMI (r = 0.38, p = 0.0022). After multivariable adjustment, every 1 ml/min/1.73 m2 increase in eGFR was associated with a 2% lower odds of a lipid abnormality (OR 0.979, p = 0.026). Obesity, hypertension, and left ventricular hypertrophy were similar between those with and without lipid abnormalities, while insulin-treated diabetes was more prevalent in recipients with lipid abnormalities (12.9% vs. 0%, p = 0.047). Only 36.5% of patients (n = 19) were referred to a dietician and/or lipid specialist; one received statin therapy. Conclusions: Lipid abnormalities are highly prevalent in pKTR, but therapeutic intervention is infrequent. Calcineurin inhibition without corticosteroids may not be protective; however, higher eGFR is associated with a lower prevalence of lipid abnormalities. [ABSTRACT FROM AUTHOR]